Advocates for psilocybin tout the substance’s affinity to treat many mental health conditions, including depression and anxiety when taken in small doses…small enough to achieve the desired health benefits but also prevent the “trippy” effects most people think of when they think of magic mushrooms.
This method is called microdosing and it’s one of the fastest-growing trends in the LikeFolio universe.
Discussions surrounding the topic are exploding, and the sample size is nothing to scoff at. We logged more than 100,000 of these topical discussions last quarter alone.
Despite this surge in interest, this trend is still in the very early stages of development.
Colorado, after all, is only the second state (behind Oregon) to legalize access to psilocybin in this nature.
But as an investor, it’s something to watch.
This treatment could serve as a solution for many consumers with mental health concerns – many of which have risen dramatically as a result of the pandemic.
So, we’re beefing up our research in this segment. You can catch up on prior write-ups about psychedelics here and here.
We’ve also added 3 major drug companies who are specializing in the development of psychedelic compounds for therapeutic treatment of many psychological issues to our coverage list. These names are live on our research dashboard for ongoing tracking:
Atai Life Sciences (ATAI)
COMPASS Pathways (CMPS)
While the world of psychedelic treatments are still in the early phases, it’s always better to be informed about potential opportunities.
In fact, we’re diving into 5 major companies leading what we’ve deemed the Healthcare Renaissance in our next MegaTrends report. These companies aren’t all involved in psychedelics, but they are leading the next wave of thought when it comes to health, wellness, and disease prevention.
Members can expect this report on Monday – we can’t wait!